Is Cardiac Prophylaxis Effective in Early HER2+ Breast Cancer Patients?


In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?

In patients with HER2-positive breast cancer treated with anthracyclines as well as trastuzumab, the addition of lisinopril or carvedilol can reduce the risk of cardiotoxicity, according to a new study.

“Trastuzumab is a highly effective therapy for HER2-positive breast cancer,” said Pamela N. Munster, MD, of the University of California, San Francisco. “However, cardiac side effects require frequent monitoring, resulting in dose interruptions and discontinuation.” She presented these results of a randomized trial in patients with early HER2-positive breast cancer at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8 (abstract GS5-01).

A total of 468 patients were randomized to receive lisinopril, carvedilol, or placebo; they were stratified based on whether or not they received anthracycline treatment. Of those, 193 patients came off the therapy before a 52-week treatment period was completed. Baseline characteristics of patients were generally similar, though those who received anthracyclines were younger (48 years vs 53 years at baseline) and had lower blood pressure.

In the full cohort, cardiotoxicity-defined as a greater than 10% decrease in left ventricular ejection fraction (LVEF), or a drop larger than 5% in those with LVEF below 50%-was reported at similar rates across the placebo (32%), lisinopril (30%), and carvedilol (29%) groups. Compared with placebo, lisinopril yielded a hazard ratio (HR) for cardiotoxicity of 0.74 (95% CI, 0.48–1.12; P = .076); for carvedilol, the HR was 0.71 (95% CI, 0.47–1.07; P = .052).

When separated based on anthracycline treatment, though, the therapies did offer benefit. In just those who received anthracyclines, the HR for cardiotoxicity with lisinopril was 0.53 (95% CI, 0.30–0.94; P = .015). For carvedilol, the HR was 0.49 (95% CI, 0.27–0.89; P = .009).

Munster said the drugs were well tolerated, with virtually no grade 3 toxicity associated with lisinopril or carvedilol. There was more fatigue, dizziness, cough, and hypertension with lisinopril than with carvedilol.

“In patients with HER2-positive breast cancer treated with trastuzumab, should you choose to use an anthracycline, the addition of lisinopril or carvedilol should be considered,” Munster concluded.

Jennifer Ligibel, MD, of Dana-Farber Cancer Institute in Boston, was the discussant for the study, and she said the study was well designed and is the largest trial to date looking at this sort of prevention in HER2-positive patients. She also noted that the results in those receiving taxanes rather than anthracyclines are reassuring, given that cardiotoxicity does not appear to be a significant risk.

In the anthracycline group, though, she wondered “whether we want to be adding a new medication for a change in echocardiogram without clinical congestive heart failure.” The study did not include women with baseline cardiac risk factors, and though there was clearly a benefit with lisinopril and carvedilol, further research may still be needed. “I think we need a bit more information in order to be routinely prescribing these medications,” Ligibel said.

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.
An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.
Related Content